ARTICLE | Clinical News
Lilly halts tabalumab for lupus
October 3, 2014 3:06 AM UTC
Eli Lilly and Co. (NYSE:LLY) said it will discontinue development of tabalumab to treat systemic lupus erythematosus (SLE) because it failed to show sufficient efficacy in two Phase III trials. The pharma said its decision was not based on safety concerns.
The human IgG4 mAb targeting BLyS (BAFF) did not meet the primary endpoint in the ILLUMINATE 1 study at either of two doses compared to standard of care, while the higher dose met the primary endpoint in ILLUMINATE 2. The company said full trial results will be presented at a scientific forum. ...